Aging is defined as the accumulated cellular damage over time that is unrepaired. Cellular damage increases exponentially after puberty. Sirtuin enzymes are normally turned off because evolution designed our cells to be very energy efficient. As humans evolved, the body was unable to allocate energy to sufficiently continue cellular repair to prevent aging. As a result, a $192B industry was created in the anti-aging and aesthetics industry and one company, Egaceutical, has researched the anti-aging process and in turn, developed a new product that aids in human age reversal.
Egaceutical Corporation are the producers and sellers of EGA therapy (or “age” spelled backward) – a triple compound therapy. It is a water-based drink that you take twice a day in correlation with your biological clock. Each drink contains the following ingredients:
Nicotinamide mononucleotide (NMN) a compound that turns into cellular NAD,
A compound that increases methyl donor, SAM, for cellular methylation,
A compound that turns on antioxidant defense activation, Nrf2, to increase cellular antioxidant enzymes that decrease oxidation and increase cell reduction.
All three compounds act in concert with one another to provide the cellular biological pattern that allows the sirtuin enzymes, which are pattern recognizing and sensing enzymes, to turn on, stay on, stop feedback loops from turning them off which then allows age reversal to happen in humans.
EGA physically controls three major pathways in cellular biology: 1. an energy-sensing pathway that senses low energy from NAD+ (as well as NAD+ removal by CD-38) and cAMP; 2. a methylation pathway that also regulates RNA transcription (the turning on of DNA, also called epigenetics); and 3. the reduction/oxidation pathways (REDOX) that are sensed by sulphur-containing thiol groups of proteins.
Nicotinamide mononucleotide (NMN) is the only compound that has been demonstrated to reverse aging in mammals, including humans.
The first international patent application for human age reversal was recently filed by Egaceutical. The EGA therapy is based off previous research in mice at Washington University School of Medicine and Harvard Medical School. The trials showed that sirtuins are turned on by NAD+ (ingestion of the NAD+ precursor nicotinamide mononucleotide, NMN, that turns into NAD+).
Additional early Egaceutical research showed NAD+ can turn on sirtuins in humans, but sirtuins, even with available NAD+, can be turned off by cellular feedback loops. This patent solves that problem of human repair being turned off, and also solves the problem of NAD+ and NMN being degraded by the enzyme CD-38. CD-38 increases with age, causing NAD+ to decrease with age.
Egaceutical’s therapy turns on sirtuins and keeps the human feedback loops from turning sirtuins off, as well as keeping CD-38 off, so that CD-38 does not degrade NAD+ and NMN before they can be used to power repair.
Aging is defined as the accumulated cellular damage over time that is unrepaired. Cellular damage increases exponentially after puberty. Sirtuin enzymes are normally turned off because evolution designed our cells to be very energy efficient. In evolution, our ancestors were not able to get all the energy from food they would have benefited from and evolution did not allocate energy to keep on cellular repair sufficiently to prevent aging.
The initial Egaceutical study showed reversal of biological age with EGA in 12 human males from age 46 to 66 with no negative side effects. Egaceutical will not seek FDA approval to market EGA for human age reversal, as “aging” is not classified as a disease by the FDA.
In addition to the youthful feelings in the treated individuals, proof of biological age reversal comes from the changes (decreases) in molecular biological markers (examples: IL-6 and TNF-alpha) that Egaceutical Corporation found in study subjects that took EGA.
A larger double-blind, placebo-controlled study for EGA is now being planned by the University of California, San Diego School of Medicine for the benefit of the scientific and medical community. Egaceutical Corporation is presently raising $25 million to fund this study.
For more information on Egaceuticals, visit the company’s website.